Compile Data Set for Download or QSAR
Report error Found 205 Enz. Inhib. hit(s) with all data for entry = 6700
TargetCyclin-dependent kinase 4(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148254BDBM148254(US8962630, 63)
Affinity DataIC50: 8nMpH: 7.5 T: 2°CAssay Description:A 384-well microtiter Lance TR-FRET (time-resolved-fluorescence energy transfer) endpoint assay was used for CDK4/cyclin D1 kinase activity measureme...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148264BDBM148264(US8962630, 74 | Ribociclib | LEE011 | Kisqali | 7-...)
Affinity DataIC50: 10nMpH: 7.5 T: 2°CAssay Description:A 384-well microtiter Lance TR-FRET (time-resolved-fluorescence energy transfer) endpoint assay was used for CDK4/cyclin D1 kinase activity measureme...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 4(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148218BDBM148218(US8962630, 26)
Affinity DataIC50: 26nMpH: 7.5 T: 2°CAssay Description:A 384-well microtiter Lance TR-FRET (time-resolved-fluorescence energy transfer) endpoint assay was used for CDK4/cyclin D1 kinase activity measureme...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 1(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148210BDBM148210(US8962630, 18)
Affinity DataIC50: 1.10E+3nMT: 2°CAssay Description:A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 1(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148203BDBM148203(US8962630, 11)
Affinity DataIC50: 1.30E+3nMT: 2°CAssay Description:A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 1(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148238BDBM148238(US8962630, 47)
Affinity DataIC50: 2.60E+3nMT: 2°CAssay Description:A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148210BDBM148210(US8962630, 18)
Affinity DataIC50: 2.80E+3nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148226BDBM148226(US8962630, 35)
Affinity DataIC50: 2.90E+3nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148203BDBM148203(US8962630, 11)
Affinity DataIC50: 3.50E+3nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148232BDBM148232(US8962630, 41)
Affinity DataIC50: 4.70E+3nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 1(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148226BDBM148226(US8962630, 35)
Affinity DataIC50: 4.70E+3nMT: 2°CAssay Description:A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148199BDBM148199(US8962630, 8)
Affinity DataIC50: 8.00E+3nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148238BDBM148238(US8962630, 47)
Affinity DataIC50: 8.30E+3nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 1(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148202BDBM148202(US8962630, 10A)
Affinity DataIC50: 1.20E+4nMT: 2°CAssay Description:A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 1(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148277BDBM148277(US8962630, 87)
Affinity DataIC50: 1.30E+4nMT: 2°CAssay Description:A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148202BDBM148202(US8962630, 10A)
Affinity DataIC50: 1.40E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 1(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148199BDBM148199(US8962630, 8)
Affinity DataIC50: 1.40E+4nMT: 2°CAssay Description:A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 1(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148232BDBM148232(US8962630, 41)
Affinity DataIC50: 1.48E+4nMT: 2°CAssay Description:A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148223BDBM148223(US8962630, 32)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148250BDBM148250(US8962630, 59)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148273BDBM148273(US8962630, 83)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148196BDBM148196(US8962630, 4)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148205BDBM148205(US8962630, 13)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148230BDBM148230(US8962630, 39)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148246BDBM148246(US8962630, 55)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148251BDBM148251(US8962630, 60)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148252BDBM148252(US8962630, 61)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148253BDBM148253(US8962630, 62)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148225BDBM148225(US8962630, 34)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148233BDBM148233(US8962630, 42)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148234BDBM148234(US8962630, 43)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148245BDBM148245(US8962630, 54)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148267BDBM148267(US8962630, 77)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148275BDBM148275(US8962630, 85)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148256BDBM148256(US8962630, 66)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148195BDBM148195(US8962630, 3)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148255BDBM148255(US8962630, 65)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148263BDBM148263(US8962630, 73)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148265BDBM148265(US8962630, 75)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148266BDBM148266(US8962630, 76)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148277BDBM148277(US8962630, 87)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148197BDBM148197(US8962630, 6)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148212BDBM148212(US8962630, 20)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148244BDBM148244(US8962630, 53)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148240BDBM148240(US8962630, 49)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148284BDBM148284(US8962630, 96)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148241BDBM148241(US8962630, 50)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148257BDBM148257(US8962630, 67)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148260BDBM148260(US8962630, 70)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandChemical structure of BindingDB Monomer ID 148228BDBM148228(US8962630, 37)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2015
Entry Details
US Patent

Displayed 1 to 50 (of 205 total ) | Next | Last >>
Jump to: